HALOZYME THERAPEUTICS, INC.
Company Stats
- Market Cap
- $12.5B
- as of Sep 30, 2026
- Enterprise Value
- $14.6B
- Shares Outstanding
- 113.5M
- Free Float
- 84.9%
Income Statement
- Revenue
- $1.4B
- Operating Income
- $469.0M
- Net Income
- $316.9M
- EBITDA
- $480.4M
- Revenue Growth, 3Y
- 28.4%
- FCF Margin, 3Y Avg
- 45.8%
- FCF Margin, Worst Year
- 45.0%
Cash Flow
- Free Cash Flow
- $644.6M
- FCF Yield
- 5.1%
- Owner FCF Yield
- 4.7%
Balance Sheet
- Cash & Equivalents
- $133.8M
- Total Debt
- $2.2B
- Net Debt
- $2.0B
- Net Debt / EBITDA
- 4.26x
- EV / EBITDA
- 30.34x
- Net Debt / EBIT
- 4.36x
Returns & Capital
- Share Repurchases
- $342.4M
- Buyback Yield, 3Y Avg
- 2.6%
- SBC, 3Y Avg
- $43.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.4B | $644.6M | 46.2% |
| FY2024 | $1.0B | $468.4M | 46.1% |
| FY2023 | $829.3M | $373.3M | 45.0% |
| FY2022 | $660.1M | $235.3M | 35.6% |
| FY2021 | $443.3M | $298.0M | 67.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 10, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings Roundup for Week of Nov. 2, 2026
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back